Tkaczuk A, Trivedi S, Mody MD, et al. - In this retrospective review, researchers tested the safety and effectiveness of utilizing parenteral bevacizumab in the management of severe recurrent respiratory papillomatosis (RRP), defined as having a high disease burden, frequent need for debridement, and/or tracheobronchial disease, in adults. Study participants were initially treated with 15 mg/kg of bevacizumab at 3‐week intervals. A median of 8.5 (range 2–17) infusions of bevacizumab were received by 14 adults over approximately 24 months. Intravenous bevacizumab appears clinically effective and safe for the primary treatment of severe RRP in adults. Bevacizumab-related predicted and usually mild side effects have been observed. Continued analysis of bevacizumab is warranted via a prospective clinical trial.